1	Predicting emergent Dolutegravir resistance in South Africa:
2	A modelling study
3 4 5 6	Tom Loosli ^{1,2} , Anthony Hauser ^{1,2,3,4} , Johannes Josi ^{1,2} , Nuri Han ^{1,2} , Suzanne M Ingle ⁵ , Ard van Sighem ⁶ , Linda Wittkop ^{7,8,9} , Janne Vehreschild ^{10,11,12} , Francesca Ceccherini-Silberstein ¹³ , Gary Maartens ¹⁴ , M John Gill ^{15,16} , Caroline A Sabin ¹⁷ , Leigh F Johnson ¹⁸ , Richard Lessells ^{19,20} , Huldrych F Günthard ^{1,2} , Matthias Egger ^{3,5,18} , Roger D Kouyos ^{1,2}
8 9 10 11 12	 Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland (Tom Loosli Msc, Anthony Hauser PhD, Johannes Josi PhD, Nuri Han Msc, Prof Huldrych F Günthard MD, Prof Roger D Kouyos PhD) Institute of Medical Virology, University of Zurich, Zurich, Switzerland (Tom Loosli, Anthony Hauser, Johannes Josi, Nuri Han, Prof Huldrych F Günthard, Prof Roger D Kouyos) Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland (Anthony Hauser, Prof Matthias
13 14 15 16 17	Egger MD) 4. INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France (Anthony Hauser) 5. Population Health Sciences, Bristol Medical School, University of Bristol, UK (Suzanne M. Ingle PhD, Prof Matthias Egger) 6. Stichting hiv monitoring, Amsterdam, the Netherlands (Ard van Sighem PhD) 7. Univ. Bordeaux, INSERM, Institut Bergonié BPH U1219, CIC-EC 1401, Bordeaux, F-33000, France (Prof Linda Wittkop PhD)
18 19 20	8. INRIA SISTM Team, Talence, France (Prof Linda Wittkop) 9. CHU de Bordeaux, Service d'information Médicale, INSERM, Institut Bergonié, CIC-EC 1401, Bordeaux, F-33000, France (Prof Linda Wittkop)
21 22	10. Department II of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, Frankfurt Am Main, Germany (Prof Janne Vehreschild MD)
23 24	11. Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany (Prof Janne Vehreschild)
25 26 27	12. German Centre for Infection Research (DZIF), Partner Site Bonn [®] Cologne, Cologne, Germany (Prof Janne Vehreschild) 13. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy (Prof Francesca Ceccherini- Silberstein PhD)
28 29	14. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa (Prof Gary Maartens MD)
30 31	15. Southern Alberta Clinic, Calgary, AB, Canada (Prof M John Gill MD) 16. Department of Medicine, University of Calgary, Calgary, AB, Canada (Prof M John Gill)
32 33 24	 Institute for Global Health, University College London, UK (Prof Caroline A Sabin PhD) Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town,
34 35 36	19. KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South
37 38	20. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa (Richard Lessells)
39	Correspondence to:
40	Tom Loosli (tom.loosli@uzh.ch)
41	Roger Kouyos (roger.kouyos@uzh.ch)
42	
11.2	

44 Summary

Background: In response to the rising prevalence of non-nucleoside reverse transcriptase inhibitors (NNRTIs) resistance, millions of people living with HIV (PWH) have switched to dolutegravir-based antiretroviral therapy (ART). Understanding the possible emergence of dolutegravir resistance is essential for health policy and planning. We developed a mathematical model to predict the trends of dolutegravir resistance in PWH in South Africa.

50 Methods: MARISA (Modelling Antiretroviral drug Resistance In South Africa) is a deterministic 51 compartmental model consisting of four layers: (i) the cascade of care, (ii) disease progression, (iii) 52 gender, and (iv) drug resistance. MARISA was calibrated to reproduce the HIV epidemic in South 53 Africa. We assumed dolutegravir was introduced in 2020. We extended the model by including key 54 resistance mutations observed in PWH experiencing virologic failure on dolutegravir-based ART 55 (G118K, E138AKT, G140ACS, Q148HKNR, N155H, and R263K). Model outcomes were acquired (ADR) 56 and transmitted drug resistance (TDR) to dolutegravir and NNRTIs stratified by duration on failing 57 dolutegravir-based ART and under different counterfactual scenarios of switching to protease-58 inhibitor (PI)-based ART.

59 Finding: The model predicts that ADR will increase rapidly, from 18.5% (uncertainty range 12.5% to 60 25.4%) in 2023 to 46.2% (32.9% to 58.9%) in 2040. The prevalence of ADR in 2040 increased with the 61 duration of virologic failure on dolutegravir-based ART: 18.0% (12.2% to 23.7%) for 6 months of 62 failing ART compared to 54.8% (41.1% to 63.9%) for over 1.5 years. For TDR, the model predicts a 63 slow but steady increase from 0.1% (0.1% to 0.2%) in 2023 to 8.8% (4.4% to 17.3%) in 2040. 64 Transmitted NNRTI resistance will cease to increase but remain prevalent at 7.7% in 2040. Rapid 65 resistance testing-informed switching to PI-based ART would substantially reduce both ADR and 66 TDR.

67 Interpretation: The prevalence of dolutegravir ADR and TDR will likely increase, with the 10% 68 threshold of TDR possibly reached by 2035, depending on monitoring and switching strategies. The 69 increase will likely be greater in settings where resources for HIV-1 RNA monitoring and resistance 70 testing or options for switching to alternative ART regimens are limited.

Funding: Swiss National Science Foundation, National Institutes of Health, UZH URPP Evolution in
 Action

73

74 **Research in context**

75 Evidence before this study

76 Dolutegravir has demonstrated high efficacy, even in individuals with compromised backbone drugs. 77 We searched Scopus on April 15 2024, using free text words dolutegravir and resistance. We did not 78 identify any modelling studies attempting to predict dolutegravir resistance trends in the coming 79 years. A recent collaborative analysis of predominantly European cohort studies involving 599 80 people living with HIV (PWH) who underwent genotypic resistance testing at the point of 81 dolutegravir-based treatment failure showed that the risk of dolutegravir resistance increases significantly in the presence of Nucleoside Reverse Transcriptase Inhibitor (NRTI) resistance. This is 82 83 particularly concerning in settings such as South Africa, where a high proportion of individuals 84 already exhibit NRTI resistance. Indeed, recent surveys in South Africa already hint at rapidly 85 increasing levels of acquired dolutegravir resistance.

86 Added value of this study

This study is the first to model the likely dynamics of dolutegravir resistance in South Africa. Covering the period 2020 to 2040, it extends a previous model of antiretroviral drug resistance evolution in South Africa to dolutegravir-based ART. The results indicate that while dolutegravir resistance is currently low, it will increase at the population level, and transmitted dolutegravir resistance may exceed 10% by around 2035, depending on the duration PWH spend on failing dolutegravir-based ART. Interventions such as switching to protease-inhibitor (PI)-based ART based on genotypic resistance tests could reduce or even curb the rise of dolutegravir resistance.

94 Implications of all the available evidence

Dolutegravir resistance may undermine the success of integrase strand transfer inhibitor (INSTI)based ART in South Africa, where the guidelines limit drug resistance testing to PWH with repeated viral load measurements above 1,000 copies/mL and evidence of good adherence. Monitoring the evolution of dolutegravir resistance at the population level is crucial to inform future changes in guidelines on drug resistance testing and switching to PI-based ART.

101 Introduction

102 In response to the rising prevalence of drug resistance to non-nucleoside reverse transcriptase 103 inhibitors (NNRTIs), the World Health Organization (WHO) has recommended the integrase strand 104 transfer inhibitor (INSTI) dolutegravir as first- and second-line antiretroviral therapy (ART) for all 105 people living with HIV (PWH) since 2018.¹ By July 2022, dolutegravir had been adopted as the 106 preferred first-line ART in 108 countries,² including South Africa, where over 7.5 million people live 107 with HIV.³ Dolutegravir-based ART has a higher genetic barrier to resistance than the previously 108 recommended non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line regimens.⁴ 109 Dolutegravir-resistant HIV is currently rare in PWH on first-line ART but is observed more frequently in treatment-experienced people in trials,⁵ observational cohorts,^{6,7} and national surveys,⁸⁻¹⁰ A 110 111 collaborative analysis of eight large cohort studies combined data from 599 individuals, primarily 112 from Europe, who experienced viremia on dolutegravir-based ART and underwent genotypic 113 resistance testing (GRT). At least one major or accessory INSTI drug resistance mutation (DRM) was 114 found in 86 (14%) study participants, and 23 (3.8%) had high or intermediate levels of predicted resistance to dolutegravir.⁶ 115

116 In South Africa, the current treatment guidelines recommend GRT only for people who have two or 117 more viral load measurements exceeding 1,000 copies/mL and have been on dolutegravir-based or 118 protease inhibitor (PI)- ART for over two years with good adherence.¹¹ Consequently, individuals 119 often remain viremic for prolonged periods.^{12–14} Furthermore, switching to alternative regimens, 120 such as protease inhibitor (PI)-based regimens, is relatively uncommon among those on failing 121 dolutegravir-based ART.¹⁵ Together, these factors may facilitate the emergence and spread of HIV 122 drug resistance.

123 MARISA (Modelling Antiretroviral drug Resistance In South Africa) is a mathematical model that 124 simulates the HIV epidemic and NNRTI resistance dynamics in South Africa.^{16,17} We updated the 125 model to include a dimension for dolutegravir resistance, allowing us to study the emergence of 126 acquired and transmitted resistance to dolutegravir. We aimed to predict how dolutegravir 127 resistance levels will change over time to assess if the drug will stay effective in the long run or if 128 resistance will rise rapidly, similar to what happened with the NNRTIs.

130 Methods

131 The MARISA model

Described in detail elsewhere,¹⁶ MARISA is a deterministic compartmental model of the HIV-1 132 133 epidemic in South Africa from 2005 to 2040 using monthly time steps. Briefly, it consists of four 134 dimensions: i) the continuum of care from HIV infection through to the diagnosis and initiation of 135 ART, suppressive ART (viral load < 1'000 copies per ml) and failing ART (viral load \geq 1'000 copies per 136 ml), and possible transfer to PI-based ART; ii) disease progression, with four CD4 count groups (> 137 500, 350 - 500, 200 - 349, and < 200 cells/µL); iii) gender; iv) drug resistance (appendix p3). MARISA 138 was calibrated to reproduce the HIV epidemic in South Africa using data from the IeDEA collaboration¹⁸ and the literature and fitted to estimates of the demographic and epidemiological 139 Thembisa model.¹⁹ We assumed the introduction of dolutegravir started in 2020. Rates of initiation 140 and switching to dolutegravir-based ART are described elsewhere¹⁷ and in the appendix (p4-5). 141

142 The original implementation of MARISA treated resistance as two states (susceptible or resistant), 143 which is appropriate for antiretroviral drugs with a low genetic barrier, such as NRTIs and NNRTIS. 144 However, this approach is unsuitable for dolutegravir, which has a higher genetic barrier.⁴ We 145 included the drug resistance mutations observed in the DTG RESIST study, i.e., G118K, E138AKT, G140ACS, Q148HKNR, N155H, and R263K.⁶ These six DRMs cover all mutations identified as 146 signature DRMs for dolutegravir resistance.²⁰ R263K was assumed to occur in isolation, whereas 147 148 G140ACS and Q148HKNR, and G118R and E138K occurred in combination, in line with a recent review of acquired dolutegravir drug resistance mutations.²⁰ The resulting genotypes (see Figure 1) 149 150 were classified as susceptible, potential-low, low, intermediate, and high-level dolutegravir resistance according to the Stanford resistance algorithm.²¹ As in Hauser et al.,^{16,17} we included 151 152 resistance for NRTI and NNRTI (susceptible or resistant), resulting in total in 48 drug resistance 153 compartments. We expanded the treatment cascade, stratifying the treatment failure 154 compartments according to the average duration on failing ART (< 6 months, 6 months to 1.5 years, 155 > 1.5 years). Finally, we modified the model to include out-of-care dynamics, whereby individuals on 156 failing dolutegravir-based ART may leave and re-enter care (Figure 1). See appendix p6-7 for further 157 details.

158

159 Definitions, parameters and calibration

160 We defined transmitted dolutegravir resistance as the proportion of people with intermediate or 161 high levels of dolutegravir resistance at diagnosis. Acquired drug resistance was defined as the

proportion of people on a failing dolutegravir-based regimen with intermediate or high-leveldolutegravir resistance.

164 Key model parameters included (i) acquisition and (ii) reversion rates of dolutegravir resistance 165 mutations, (iii) the impact of NRTI resistance on dolutegravir resistance acquisition, (iv) the impact of 166 dolutegravir resistance on dolutegravir treatment efficacy, (v) the probability of transmission 167 dolutegravir DRMs compared to NNRTI resistance transmission, and (vi) the proportion on failing dolutegravir-based ART with detectable drug levels. Based on the DTG RESIST study,⁶ we assume 168 169 that NRTI resistance increases the risk of acquiring dolutegravir DRMs upon treatment failure 170 (appendix page 10). We estimated mutation-specific acquisition rates based on an estimated 171 duration of 3 months of failing dolutegravir-based ART in the DTG RESIST study. The reversal of dolutegravir resistance mutations is not well documented but may occur rapidly.²² We assumed an 172 173 average duration to reversion of two years for each mutation with HIV replicating in the absence of 174 dolutegravir. We assumed that high- and intermediate-level dolutegravir resistance increases the 175 treatment failure rate on dolutegravir-based ART: for high-level resistance, the impact is equal to 176 that of high-level NNRTI resistance on NNRTI-based ART; for intermediate resistance, the effect is 177 halved. The probability of transmitting dolutegravir resistance mutations in an HIV transmission 178 event is unknown, but cases have been documented.²³ We assumed an equal transmission rate for 179 dolutegravir resistant strains as for susceptible strains, and explored decreased rates in sensitivity 180 analyses (allowing for up to 20 times decreased transmission rates in resistant strains). The 181 parameters included in MARISA and its calibration are described in detail in the appendix (p4-11).

To construct plausible ranges of model outcomes (predicted dolutegravir ADR and TDR) that reflect the uncertainty in the choice of parameter values, we defined an uncertainty range using pessimistic (favouring the emergence of resistance) or optimistic (impeding the emergence of resistance) parameter values in addition to our baseline parameterisation (Table 1 and appendix p12).

186 **Counterfactual scenarios**

187 In counterfactual scenarios, we investigate the impact of interventions such as those proposed in 188 the RESOLVE trial²⁴ on transmitted and acquired dolutegravir resistance. Specifically, we compared 189 our baseline scenario, where current treatment guidelines in South Africa are modelled, with two 190 alternative scenarios, where measures to reduce dolutegravir resistance are modelled: i) upon 191 entering failing dolutegravir compartments, people are switched to initiating PI-based ART within an 192 average time of 6 or 12 months, and ii) upon an average time of 6 or 12 months on failing 193 dolutegravir-based ART, people with intermediate or high level dolutegravir resistance are switched 194 to PI-based ART within an average time of 6 months (representing the duration taken for druglevel-

and resistance testing, receiving results, and implementing treatment adjustments). These two modelled scenarios correspond closely to the RESOLVE interventions in which i) upon detection of viral failure on dolutegravir-based ART, all people are immediately switched to PI-based ART, and ii) upon detection of viral failure on dolutegravir-based ART, all people undergo drug-level- and resistance testing, followed by switch to PI-based ART in case of resistance, and continue on dolutegravir-based ART otherwise. The appendix (p15) provides further details on the scenarios.

201

202 Sensitivity analyses

203 We investigated the effects of mutation acquisition and reversion rates by varying viremia duration 204 on dolutegravir-based ART rates from 2 to 6 months and the time for dolutegravir DRMs to revert to 205 wild type from 6 months to 20 years. Further, we varied the hazard ratio for acquiring dolutegravir 206 DRMs, comparing NRTI susceptible with resistant, from 1 (no impact) to 10. Similarly, we varied the 207 hazard ratio for failing dolutegravir-based ART associated with high-level resistance from 2 to 4. We 208 varied the probability of transmitting resistant strains from 100% (as likely as susceptible strain 209 transmission) to 5% (20 times less likely than susceptible strain transmission). Finally, we varied the 210 proportion of PWH with detectable drugs failing on dolutegravir-based ART from 0.3 to 1.

In addition to varying parameters one by one, we performed a multidimensional sensitivity analysis by implementing a Monte Carlo estimation of the first-order and total Sobol indices,²⁵ which are quantitative measures to assess the importance of parameters (and their interactions in the case of total Sobol indices) on the variability of modelled outcomes. The indices help determine relative parameter importance and identify knowledge gaps (appendix p14, p16).

216 Role of the funding source

217 The funders of the study did not participate in the study design, data collection, data analysis, data 218 interpretation, and writing of the report. The corresponding author had full access to the data of this

study and had the final responsibility for the decision to submit for publication.

221 **Results**

The model predicts a steep increase in the number of individuals on dolutegravir-based ART after its introduction in 2020, followed by a more modest but steady increase with numbers approaching eight million PWH on dolutegravir by 2040. The proportion with viral suppression in PWH on dolutegravir-based ART is estimated at around 93%, with those virally non-suppressed (viral load > 1'000 copies per ml) comprised of an increasing proportion with dolutegravir resistance (Figure 2). Among those on dolutegravir-based ART, CD4 levels continue to improve (appendix, p 14)

228 Acquired and transmitted dolutegravir resistance

229 The model predicts that acquired dolutegravir resistance in people with virologic failure on 230 dolutegravir-based ART will increase rapidly, from 18.5% (uncertainty range 12.5% to 25.4%) in 2023 231 to 46.2% (uncertainty range 32.9% to 58.9%) in 2040 (Figure 2). There were substantial differences 232 in the predicted levels of acquired dolutegravir resistance depending on the duration of failing 233 dolutegravir-based ART, with a lower prevalence in people experiencing virologic failure for 6 234 months or less and a higher prevalence among those experiencing failure for over 1.5 years. For 235 transmitted drug resistance, the model predicts a slow but steady increase from 0.1% (uncertainty 236 range 0.1% to 0.2%) in 2023 to 8.8% (uncertainty range 4.4% to 17.3%) in 2040. The rise of 237 transmitted NNRTI resistance will be broken by introducing dolutegravir, but transmitted NNRTI 238 resistance will remain prevalent at 7.7% in 2040 (Figure 2)

239 Counterfactual scenarios

240 We find that reducing the duration PWH remain viraemic whilst on dolutegravir-based ART would 241 substantially reduce acquired dolutegravir resistance at the population level. Immediately switching 242 to PI-based ART upon detecting of viral failure may reduce acquired dolutegravir resistance levels by 243 2040 from 46.2% to 14.6% and 8.2%, depending on time to detection of viral failure. If using the 244 mitigation strategy with GRT informed ART adjustment upon detection of viral failure, projected 245 acquired dolutegravir resistance may be reduced to 11.3% and 6.3% (Figure 3). Transmitted 246 dolutegravir resistance may be more than halved by 2040, from 8.8% to 2.1% and 1.1% in case of 247 immediate switching to PI-based ART, or to 3.0% and 2.3% in case of GRT informed ART adjustment 248 (Figure 3). Further details are available from the appendix (p15).

249 Sensitivity analyses

We assessed the impact of key model parameters one by one and also performed a multivariate sensitivity analysis. Perturbing one parameter at a time showed that dolutegravir resistance outcomes are affected by several variables, but the results from the main analysis were robust.

However, substantial deviations were observed for extreme parameter values, for example, assuming that the probability of transmission of dolutegravir resistance mutations was twenty times less likely than for NNRTIs, assuming much higher acquisition rates of dolutegravir resistance mutations or higher or lower reversion rates or proportion of people with detectable drug levels than in the main analysis. (appendix p16-18)

258 The variance-based global sensitivity analysis showed that predicted dolutegravir ADR was strongly 259 influenced by assumptions regarding the proportion of people with detectable drug levels (Total 260 Sobol' sensitivity index 0.34; 95% CI 0.30 to 0.38), and mutation acquisition rates (0.30; 95% CI 0.27 261 to 0.33). Assumptions for the impact of NRTI resistance on dolutegravir resistance acquisition and of 262 dolutegravir resistance on efficacy also affected ADR predictions (0.19; 95% CI 0.17 to 0.21 and 0.16; 263 95% CI 0.14 to 0.18, respectively). The assumed dolutegravir DRM transmission probability 264 compared to NNRTIs was the most important factor for the uncertainty in predicted dolutegravir 265 TDR (0.64; 95% CI 0.56 to 0.70). Mutation reversion rates also affected TDR predictions (0.20; 95% CI 266 0.16 to 0.23).

268 Discussion

269 Summary of findings

270 The transition to dolutegravir-based antiretroviral therapy (ART) has contained NNRTI resistance as a 271 threat to the long-term effectiveness of ART. Still, reliance on INSTIs for first-line and second-line 272 ART and prevention of HIV transmission carries the risk of emerging drug resistance to dolutegravir. We updated MARISA, a mathematical model of antiretroviral drug resistance, to study the 273 emergence of resistance to dolutegravir in South Africa.^{16,17} The model fitted the South African data 274 275 well, with the modelled proportion of PWH with viral suppression (around 93%) in line with 276 empirical data²⁶ and the 92% estimate reported by UNAIDS.²⁷ We found that the prevalence of 277 acquired and transmitted dolutegravir resistance will likely increase. The 10% threshold of 278 transmitted drug resistance, above which WHO recommends the replacement of a drug, could be 279 reached by 2035, depending on the monitoring and switching strategies in place. During the same 280 period, the prevalence of transmitted NNRTI will decline and then plateau at around 8%. Timely 281 switching of PWH experiencing virologic failure to PI-based ART would substantially reduce acquired 282 and transmitted drug resistance.

283 Modelled resistance in context with empirical data

284 Currently, viral suppression rates on dolutegravir are high. Although acquired drug resistance is rare, it can occur, especially in individuals with a compromised NRTI backbone.^{6,7} Transmission of 285 dolutegravir resistance has also recently been documented.²³ Programmatic data on dolutegravir 286 287 resistance in resource-limited settings are scarce. Nationally representative HIV drug resistance 288 surveys based on remnant routine diagnostic viral load samples in South Africa suggest increasing levels of dolutegravir resistance. Steegen et al.⁹ found that in samples with viral load >1000 289 290 copies/mL and detectable dolutegravir, resistance to dolutegravir increased from 2.7% in 2021 to 291 11.1% in 2022, consistent with our predictions. Similar proportions of PWH with resistance 292 mutations on failing dolutegravir-based ART have been recently reported by Tschumi et al. in 293 Lesotho,⁷ and by the WHO from other countries in Southern Africa.¹⁰

294 Duration on failing regimen

Our model predicts that acquired resistance may increase relatively quickly in the coming years. However, the predicted increase in resistance strongly depends on how long people with HIV remain viraemic on a failing dolutegravir-based regimen. There are often delays in switching, and some PWH may not be switched at all. A study linking medical and laboratory data from PWH on first-line ART in 52 South African clinics from 2007 to 2018 reported that only about 40% of PWH with confirmed virological failure were switched.²⁸ Among those who switched, the median time to

301 switch was about 16 months, with an interquartile range of 8 to 29 months.²⁸ Similarly, an analysis of 302 a South African private sector ART program found that the median time from virologic failure to 303 switching to second-line ART was about 13 months (interquartile range 8 to 22 months), with delays 304 in switching associated with increased mortality.²⁹ Other studies from sub-Saharan Africa, including 305 data from Central Africa, East Africa and West Africa, also found sub-optimal switching in adult HIV 306 cohorts after virologic failure, with delays typically ranging from 4 to 17 months.^{30–33}

307 Real-world evidence on effective switching strategies will come from the ongoing RESOLVE trial²⁴ in 308 public-sector HIV clinics in Uganda and South Africa. The trial compares universal switching to PI-309 based second-line ART with switching guided by genotypic resistance tests, urine tenofovir 310 adherence assays, and standard of care. In line with the association between the time spent on a 311 failing regimen and resistance development, the model shows that such resistance mitigation 312 strategies involving rapid switching to PI-based ART could effectively curb the increase in acquired 313 and slow down the increase in transmitted dolutegravir resistance. Both strategies could keep the 314 prevalence of dolutegravir resistance below 10% throughout the modelled period, i.e. up to 2040, in 315 case of switching or drugleveldrug level- and resistance testing, respectively, within 6 months after 316 virologic failure. Of note, the total number of people on PI-based ART differs strongly between the 317 two mitigation strategies. Implementing the immediate PI-switch strategy would result in almost 318 half of all people on ART in South Africa on PI-based ART by 2040.

319 Strengths and limitations

320 Strengths of our study include the combination of modelling the population-level epidemiology of 321 the HIV epidemic in South Africa and of INSTI, NNRTI and NRTI drug resistance, taking into account 322 the differences in the genetic barrier of these drug classes, and the model parametrisation using 323 data from a large collaborative study of dolutegravir resistance.⁶ Further, the model allowed us to 324 assess the impact of public health interventions in counterfactual scenarios. Limitations include large 325 parameter uncertainty, particularly regarding mutation pathways and acquisition- and reversion 326 rates, which we addressed in the sensitivity analyses. The global sensitivity analysis helped unravel 327 the relative importance of these parameters, and identified key knowledge gaps in our 328 understanding of dolutegravir resistance dynamics. The limited data available on drug resistance 329 mutation and their accumulation is a further limitation that may only be addressed in the future 330 when more data becomes available. There is also uncertainty about the interactions between DRM's 331 impact on viral fitness, including the role of compensatory mutations and the transmission of DRMs. 332 This uncertainty affects transmitted drug resistance more than acquired, as reflected in the broader 333 range of modelled outcomes for transmitted drug resistance. The assumed treatment cascade is a

- 334 simplification. For example, more complicated treatment histories or the dis- and re-engagement in
- care³⁴ that may favour the emergence of resistance were not explicitly modelled.

336 Conclusions

337 In conclusion, this modelling study indicates that dolutegravir resistance may increase considerably 338 in South Africa: without changes in the management of virologic failure on dolutegravir-based ART, 339 the emergence of transmitted dolutegravir resistance appears to be a question of when, not if, and 340 acquired dolutegravir resistance may increase rapidly in the near future. Drug resistance mitigation 341 strategies for those with virologic failure on dolutegravir-based ART, such as GRT-informed ART 342 adjustment, could strongly reduce acquired and transmitted dolutegravir resistance if virologic 343 failure is detected rapidly. We conclude that dolutegravir resistance surveillance including enhanced 344 viral load monitoring and genotypic resistance testing should be strengthened, especially in settings 345 with programmatic use of dolutegravir-based ART where people remain longer on failing ART. Greater access to genotypic resistance testing³⁵ as well as low-cost rapid point-of-care tests of 346 antiretroviral drug levels,³⁶ and making generic darunavir/ritonavir available for around 200 US 347 dollars per patient per year³⁷ should increase rates of switching to second-line ART and reduce 348 349 delays, and thereby curbing the emergence and spread of dolutegravir resistance.

351 Figures & Table

352

Table 1: Key dolutegravir resistance parameters. Modelled prospective scenarios include baseline parameter values, and
 ranges using pre-defined in - and decreased resistance parameters to derive an uncertainty interval. Other parameters used
 in the model can be found in the appendix p4-11. Abbreviations: DRM: drug resistance mutation.

356

			Uncertainty range	
Parameter	Description	Baseline	Pessimistic choice in parameter values	Optimistic choice in parameter values
1 / r _{DRM}	Mean time for dolutegravir DRMs to revert (years)	2	3	2
α _{NRTI→DTG}	Impact of NRTI resistance on dolutegravir DRM acquisition rates (hazard ratio vs susceptible)	4	5	3
$\alpha_{impactDTG}$	Impact of high-level dolutegravir resistance on dolutegravir efficacy (hazard ratio vs susceptible)	3.24	2	4
Φtransmission DTG	Probability of dolutegravir resistance transmission compared to NNRTI resistance transmission	Same	Same	-20%
Pdrug detect	Proportion with detectable drugs on failing dolutegravir-based ART	0.626	0.814	0.482

Note: For all scenarios, mutation rates were calculated based on assumed time of 3 months on failing dolutegravir-based ART (see appendix p7-8).



359360 Figure 1: Simplified schematic overview of the adapted MARISA model. The treatment dimension, including dolutegravir

361 resistance acquisition on failing dolutegravir-based ART, is shown. Not displayed here are the dimensions for gender and

362 CD4 levels, NNRTI- and NRTI resistance acquisition, and mortality. Details on the model structure can be found in the363 appendix p3-11.

358





Figure 2: Modelled viral suppression on DTG-based ART, acquired and transmitted dolutegravir resistance. Solid lines 368 show baseline parameterisation regarding mutation reversion rates, impact of NRTI resistance on dolutegravir DRM 369 acquisition, impact of dolutegravir resistance on its efficacy, transmission probability of dolutegravir DRMs in an HIV 370 transmission event, and proportion with detectable druglevelsdrug levels on failing dolutegravir-based ART. Shaded areas 371 correspond uncertainty intervals (see appendix p12). Dolutegravir rollout was started in 2020. Viral suppression (viral load 372 below 1'000 copies per ml) on dolutegravir-based ART is high; depending on the model assumptions for dolutegravir 373 resistance (see uncertainty range), between 6% and 8% of people on dolutegravir-based ART may be virally unsuppressed . 374 Acquired dolutegravir resistance is defined as proportion of people on a failing dolutegravir-based ART with intermediate-375 or high-level dolutegravir resistance. Transmitted dolutegravir resistance is defined as proportion of newly diagnosed 376 people with intermediate- or high-level dolutegravir resistance. 377



379 380

Figure 3: Counterfactual scenario, modelling resistance emergence mitigation strategies. Both strategies reduce the 381 duration with viremia on dolutegravir-based ART. GRT-informed ART adjustment includes druglevel testing and genotypic 382 resistance testing upon detecting virologic failure, followed by switching to PI-based ART in case of intermediate or high 383 level dolutegravir resistance. Immediate PI switch includes switching people with virologic failure on dolutegravir-based 384 ART immediately to PI-based ART. Modelled scenarios include projections assuming 6 and 12 months until virologic failure 385 is detected (6 months: dark blue and dark red lines; 12 months: light blue and light red lines) upon which the respective 386 strategy is implemented immediately. In case of drugleveldrug level-and genotypic resistance testing, we assume an 387 additional average duration of 6 months from detection of virologic failure to informed treatment adjustment. Acquired 388 dolutegravir resistance is defined as proportion of people on a failing dolutegravir-based ART with intermediate- or high-389 level dolutegravir resistance. Transmitted dolutegravir resistance is defined as proportion of newly diagnosed people with 390 intermediate- or high-level dolutegravir resistance..

392 Authors' contributions

RDK, RL, ME, and HFG conceptualised the study. TL, JJ, and RDK curated the data. TL, AH, JJ, and RDK devised the methodology. TL, NH, and JJ conducted the formal analysis and validation. TL, NH, and JJ managed the data. RDK provided project administration. AH and ME contributed resources. TL, NH, and JJ applied and adapted the software. HFG, RL, ME, LFJ, AH, and RDK provided supervision. TL created the figures. TL and RDK wrote the original draft of the manuscript. All authors reviewed the manuscript. TL, NH and RDK have directly accessed and verified the underlying data reported in the manuscript. All authors had the final responsibility for the decision to submit for publication.

400

401 **Declaration of interests**

402 RDK reports grants from the Swiss National Science Foundation, the National Institutes of Health, 403 and Gilead Sciences. MJG has served as an ad hoc advisor to Gilead, ViiV and Merck. RDK reports 404 grants from the Swiss National Science Foundation, the National Institutes of Health, and Gilead 405 Sciences. H. F. G. has received grants from the Swiss National Science Foundation, Swiss HIV Cohort 406 Study, Yvonne Jacob Foundation, University of Zurich's Clinical Research Priority Program, Zurich 407 Primary HIV Infection, Systems.X, Bill and Melinda Gates Foundation, NIH, Gilead Sciences, ViiV and 408 Roche; personal fees from Merck, Gilead Sciences, ViiV, Janssen, GSK, Johnson & Johnson, and 409 Novartis for consultancy or data and safety monitoring board membership; and a travel grant from 410 Gilead. LW has received grants from the ANRS emerging infectious diseases ANRS MIE, European 411 Union (projects funded via H2020, Horizon Europe). SMI reports grant funding by the NIH National 412 Institute on Alcohol Abuse and Alcoholism (U01-AA026209, payment to institution). F.C.S has 413 received grants from the Italian Istituto Superiore di Sanità, Italian Ministry of Health, Italian 414 Ministry of University and Scientific Research, University of Rome Tor Vergata, European Union 415 (projects funded via H2020, Horizon Europe), ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp 416 & Dohme, Inc.; personal fees for consultancy from ViiV Healthcare, Gilead Sciences, Inc, and Merck 417 Sharp & Dohme, Inc. All other authors declare no competing interests.

418

419 Acknowledgements

This work was supported by the University Research Priority Program 'Evolution in Action', the Swiss National Science Foundation (324730_207957), and the NIH National Institute of Allergy and Infectious Diseases under award number R01AI152772. We thank the DTG RESIST study group for helpful discussions.

424 **References**

425 1. WHO. Update of recommendations on first- and second-line antiretroviral regimens. Geneva, 426 Switzerland: World Health Organization; WHO. 2019. p. 3. 427 2. WHO. WHO HIV Policy Adoption and Implementation Status in Countries [Internet]. HIV 428 Treatment and Care Fact Sheet. 2022. p. 1–6. Available from: 429 https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/who-hiv-430 policy-adoption-and-implementation-status-in-countries nov.pdf?sfvrsn=bb35e6ae 8 431 [Accessed: 18.04.2023] 432 3. UNAIDS. Global HIV & amp; AIDS statistics — 2020 fact sheet | UNAIDS [Internet]. [cited 2020 433 Jul 10]. Available from: https://www.unaids.org/en/resources/fact-sheet 434 4. Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to 435 resistance for dolutegravir. AIDS Rev. 2015;17(1):56-64. 436 5. Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Efficacy and safety 437 of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or 438 tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a 439 prospective, multicentre, open-label, factorial, randomised, no. Lancet HIV. 2022;1–13. 440 6. Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, et al. HIV-1 drug resistance in 441 people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Lancet 442 HIV. 2023 Oct 10; 443 7. Tschumi N, Lukau B, Tlali K, Motaboli L, Kao M, Kopo M, et al. Emergence of acquired 444 dolutegravir resistance in treatment-experienced people with HIV in Lesotho. Clin Infect Dis. 445 2024 Apr; 446 8. Kamori D, Barabona G, Rugemalila J, Maokola W, Masoud SS, Mizinduko M, et al. Emerging 447 integrase strand transfer inhibitor drug resistance mutations among children and adults on 448 ART in Tanzania: findings from a national representative HIV drug resistance survey. J 449 Antimicrob Chemother. 2023;78(3):779-87. 450 9. Steegen K. Close monitoring of dolutegravir resistance in patients with laboratory confirmed 451 dolutegravir exposure: observations from a national HIV drug resistance survey in South 452 Africa. Cape Town: XXX INTERNATIONAL WORKSHOP ON HIV DRUG RESISTANCE AND 453 TREATMENT STRATEGIES; 2023. 454 10. WHO. HIV drug resistance: brief report 2024. Geneva: World Health Organization; 2024. 455 11. South African National Department of Health. 2023 ART Clinical Guidelines for the 456 Management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents, Children, Infants 457 and Neonates. 2023; 458 12. Chimukangara B, Lessells RJ, Sartorius B, Gounder L, Manyana S, Pillay M, et al. HIV-1 drug 459 resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in 460 KwaZulu-Natal Province, South Africa. J Glob Antimicrob Resist. 2022;29:468–75. 461 13. Fox MP, Cutsem G V, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of 462 failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J 463 Acquir Immune Defic Syndr. 2012;60(4):428-37. 464 14. Manasa J, Lessells RJ, Skingsley A, Naidu KK, Newell M-L, McGrath N, et al. High-Levels of 465 Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural 466 HIV Treatment Programme in KwaZulu-Natal, South Africa. PLoS One. 2013;8(8).

467 468 469	15.	Venter WDF, Kaiser B, Pillay Y, Conradie F, Gomez GB, Clayden P, et al. Cutting the cost of South African antiretroviral therapy using newer, safer drugs. Vol. 107, SAMJ: South African Medical Journal. scieloza; 2017. p. 28–30.
470 471 472	16.	Hauser A, Kusejko K, Johnson LF, Wandeler G, Riou J, Goldstein F, et al. Bridging the gap between hiv epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in south africa. PLoS Comput Biol. 2019;15(6):1–17.
473 474 475	17.	Hauser A, Kusejko K, Johnson LF, Günthard HF, Riou J, Wandeler G, et al. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. PLoS Med. 2020;17(12).
476 477 478	18.	Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al. International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. BMJ Open. 2020;10(5).
479 480 481	19.	Johnson LF, Dorrington R. Thembisa version 4.1: A model for evaluating the impact of HIV/AIDS in South Africa [Internet]. 2018. Available from: https://www.thembisa.org/publications
482 483 484	20.	Tao K, Rhee S-Y, Chu C, Avalos A, Ahluwalia AK, Gupta RK, et al. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review. Viruses. 2023;15(9).
485 486 487	21.	Rhee S-Y, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31(1):298–303.
488 489 490	22.	Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, et al. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect. 2011;17(6):928–34.
491 492 493	23.	Francois K, Van Onacker JD, Jordan MR, Journel I, Buteaue J, Pierre E, et al. First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers. AIDS. 2023;37(13):2097–9.
494 495 496 497	24.	McCluskey S. A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa (RESOLVE) [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); [cited 2024 Jul 15]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05373758
498 499 500	25.	Saltelli A, Annoni P, Azzini I, Campolongo F, Ratto M, Tarantola S. Variance based sensitivity analysis of model output. Design and estimator for the total sensitivity index. Comput Phys Commun. 2010;181(2):259–70.
501 502 503 504	26.	Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, et al. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study. Lancet HIV. 2023;10(5):e284– 94.
505	27.	UNAIDS: Joint United Nations Programme On HIV/AIDS. UNAIDS data 2023. Geneva; 2023.
506 507 508	28.	Hermans LE, Carmona S, Nijhuis M, Tempelman HA, Richman DD, Moorhouse M, et al. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study. PLoS Med. 2020;17(2):e1003037.
509	29.	Bell Gorrod H, Court R, Schomaker M, Maartens G, Murphy RA. Increased Mortality with

510 Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. J Acquir 511 Immune Defic Syndr. 2020;84(1):107-13. 512 30. Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, et al. Delayed switch of 513 antiretroviral therapy after virologic failure associated with elevated mortality among HIV-514 infected adults in Africa. AIDS. 2014;28(14):2097-107. 515 31. Ssempijja V, Nakigozi G, Chang L, Gray R, Wawer M, Ndyanabo A, et al. Rates of switching to 516 second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, 517 and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. 518 BMC Infect Dis. 2017;17(1). 519 32. Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and 520 switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: 521 Collaborative analysis. Lancet HIV. 2015;2(7):e271-8. 522 33. Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JBT, Boyer S, et al. 523 Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical 524 monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall 525 ANRS 12110/ESTHER): A randomised non-inferiority trial. Lancet Infect Dis. 2011;11(11):825-526 33. 527 34. Euvrard J, Timmerman V, Keene CM, Phelanyane F, Heekes A, Rice BD, et al. The cyclical 528 cascade of HIV care: Temporal care engagement trends within a population-wide cohort. 529 PLoS Med. 2024;21(5). 530 35. de Oliveira T, Baxter C. Investing in Africa's scientific future. Science. 2024 Mar 531 6;383(6678):eadn4168. 532 36. Dorward J, Lessells R, Govender K, Moodley P, Samsunder N, Sookrajh Y, et al. Diagnostic 533 accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug 534 resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy. J 535 Int AIDS Soc. 2023;26(9). 536 37. World Health Organization. Innovative agreement launches affordable, optimal second-line 537 HIV treatment in low- and middle-income countries [Internet]. 2021. Available from: 538 https://unitaid.org/news-blog/innovative-agreement-affordable-optimal-second-line-hiv-539 treatment/#en 540